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Over the past decade, irinotecan has become one of the first-line chemotherapeutic agents used in the treatment of metastatic
colorectal cancer. Recently, irinotecan has been administered transarterially in order to perform chemoembolization in the liver.
In the limited number of reports available to date using this approach, serious adverse effects have not yet been reported. In this
paper, we describe the formation of an intercostal artery pseudoaneurysm after transarterial chemoembolization with irinotecan-
eluting beads in a patient with spinal metastasis from colorectal cancer.
1. Introduction
Approximately 20% of patients with colorectal cancer (CRC)
present with metastatic disease at the time of diagnosis
[1]. Currently, surgical resection is the standard of care for
patients with isolated metastases from CRC, improving 5-
year survival rates up to 32.5% from 10.5% [1]. However,
surgical resection can only be performed in 10% of patients
[1]; therefore converting initially unresectable metastases
into resectable metastases is a crucial step in the management
of patients with metastatic CRC. For the past ten years, 5-
fluorouracil (5-FU) and oxaliplatin have been used as first-
line therapies [2] in the downstaging of metastatic CRC,
although recently newer drugs such as irinotecan have been
shown to be effective [2].
Irinotecan (Camptosar) is a chemotherapeutic drug
that has become more popular over the past decade due
to its significant antitumoral activity against metastatic
colorectal cancer, although major side effects have limited its
systemic use [3]. To minimize the side effects, transarterial
chemoembolization with drug-eluting beads has been used
instead. To our knowledge, there has been no clinical report
of irinotecan chemoembolization for the treatment of meta-
static CRC to the spine in patients who are not amenable
to surgical resection or radiofrequency ablation. In addition,
there has been no clinical report of major side effects in
using irinotecan chemoembolization in the treatment of
CRC metastases to the spine. In this paper, we present a
case of an intercostal artery pseudoaneurysm that developed
after chemoembolization with irinotecan-eluting beads for a
spinal metastasis of colorectal cancer.
2. Case Presentation
Institutional review board (IRB) approval was obtained
for this case presentation. Two months prior to presen-
tation at our institution, a 44-year-old Iranian male was
diagnosed with adenocarcinoma of the colon. Initially,
the patient received a low anterior resection and lymph
node dissection which demonstrated extension into the
peritoneal surface with lymph nodes positive for disease
(stage T3N1). After being seen in January 2001, the patient
underwent chemotherapy with 5-flurouracil, leucovorin, and
irinotecan for six months. But in September 2002, his CT
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Figure 1: T1 post-Gadolinium fat-saturation MRI T-spine. Note
the metastatic tumor in the left paravertebral/chest wall area
extending into the epidural space with destruction of the left
transverse processes, pedicles, and vertebral bodies. Mass measures
4.0 cm in width × 5.8 cm cephalocaudally × 4.3 cm anterior-
posterior direction.
scan demonstrated a left lung nodule which was resected in
October 2002 and diagnosed as metastatic adenocarcinoma
of the colon. Postoperatively, the patient received a second
regimen of chemotherapy with 5-flurouracil, leucovorin, and
oxaliplatin for four months. Colonoscopy and serial CT
scans in 2003 did not demonstrate any recurrent disease.
But in February 2004, recurrent bilateral pulmonary nodules
were detected and surgically resected which demonstrated
again metastatic adenocarcinoma of the colon. A followup
CT in November 2004 demonstrated a left pleural mass
and bilateral lung nodules, and the patient was started on
a third regimen of chemotherapy including 5-fluorouracil,
leucovorin, irinotecan, and abciximab. In March 2006, these
lesions demonstrated progression which led to a left chest
wall resection with a portion of the lung. The lesions on
the right were planned for radiofrequency ablation therapy,
but in January 2007, the focus shifted to treating a large
paravertebral mass involving the left T7, T8, and T9 vertebral
bodies revealed on CT and MRI, which was invading
the neural foramina with epidural extension (Figure 1).
As the tumor extended into the epidural space, surgical
removal and radiofrequency ablation (RFA) of the mass were
not considered options and the patient’s spinal metastasis
was treated with chemoembolization and radiation therapy
[4].
On the day of the chemoembolization, after written
informed consent was obtained, the patient was prepped in a
normal sterile fashion. A 5 Fr sheath was placed in the right
femoral artery. An angled Glidewire (Meditech, Watertown,
MA), Mikaelsson catheter (Angiodynamics, Queensbury,
NY), Progreat catheter (Terumo, Leuven, Belgium), and
Transend wire (Boston Scientific Target, Fremont, CA)
were used to sequentially select multiple intercostal arteries
bilaterally.
After identifying the feeding vessels of the left paraverte-
bral tumor, which were the left T7, T8, and T9 intercostal
arteries, a total of 60mg of irinotecan suspended in 300–
500 µm LC Beads (Biocompatibles, Farnham, Surrey, UK)
was injected in divided doses between the left T7, T8, and T9
vertebral arteries. Due to vasospasm, only partial emboliza-
tion of the T9 intercostal artery was accomplished (Figures
2 and 3). Therefore, the patient was scheduled to return two
weeks later to receive additional chemoembolization of this
particular vessel.
Two weeks later with the intention of embolizing the
T9 intercostal artery, reintervention was performed. The
patient was prepped in a normal sterile fashion, and a
5 Fr sheath was inserted into the right common femoral
artery. A 5 Fr Mikaelsson spinal catheter was then advanced
into the left T8 through T10 intercostal arteries and the
right T8 intercostal arteries. The left T9 intercostal artery
angiogram demonstrated that the previously noted small
feeding arteries to the known tumor were no longer visible
likely because of spontaneous thrombosis. However, in the
proximal left T8 intercostal artery, a laterally projecting
outpouching of stagnant contrast was noted, consistent
with a pseudoaneurysm (Figure 4). Although a contained
aortic dissection was considered, in real time, the focal
outpouching of contrast arose from the left T8 intercostal
artery and not from the aorta. The opacifying portion of the
pseudoaneurysmmeasured about 2-3 cm in size with a 5mm
neck.
The pseudoaneurysm was embolized with a micro-
catheter system. Embolization was achieved with 16 GDC
360 coils and 5 MTI Helix coils, and the postembolization
aortogram demonstrated (1) no contrast opacification of
the pseudoaneurysm lumen, (2) a coil mass measuring
approximately 1.5×3.5 cm, and (3) a gentle regional concave
deformity of the aorta, implying that the nonthrombosed
pseudoaneurysm sac of the pseudoaneurysm was larger than
what opacified originally (Figure 5). The patient had an
uneventful hospital course following the procedure and was
discharged the following day. Although the patient had noted
having new low grade left-sided chest discomfort for two
weeks between the first two chemoembolization procedures,
upon followup one month later, the patient reported that
his chest discomfort had resolved. In addition, his CEA
decreased from 11 ng/mL before procedure to 5.5 ng/mL
after procedure. Postembolization imaging demonstrated a
decrease in size of the spinal metastasis from 6.6 cm× 6.2 cm
on preprocedure CT to 5.5 cm×5.2 cm on postprocedure CT
(Figure 6).
3. Discussion
Irinotecan (Camptosar) is a chemotherapeutic drug that
has become more popular over the past decade due to its
significant anti-tumoral activity against metastatic colorectal
cancer [3]. It inhibits cancer growth primarily by inhibiting
topoisomerase I in actively dividing tumor cells [3]. When
used separately, the efficacy of irinotecan was comparable to
5-FU; used together, synergistic improvement in efficacy was
shown [5]. Despite the improvements in the overall survival
of patients treated with irinotecan, major side effects such as
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Figure 2: Before TACE with irinotecan-eluting beads. Selections of the (a) left T7 intercostal artery, (b) left T8 intercostal artery, and (c) left
T9 intercostal artery. Note the small branches from these intercostal arteries supplying the spinal metastasis from colorectal cancer.
Figure 3: Left T9 intercostal artery immediately after TACE
with irinotecan-eluting beads. Note that there is a small branch
off of the T9 intercostal artery which still seems to supply the
tumor, indicating the need to repeat the procedure in two weeks
to completely chemoembolize the branch with irinotecan-eluting
beads.
grade 3-4 diarrhea and neutropenia [6, 7] limit the systemic
use of irinotecan [3].
To minimize the side effects, transarterial chemoem-
bolization with drug-eluting beads has been used. With
chemoembolization, there is a significant reduction of these
systemic side effects with only mild abdominal and shoulder
pain, vomiting and mild asthenia, and some alopecia [6].
No serious side effects such as diarrhea and neutropenia
were reported, supporting the premise that this approach
Figure 4: Two weeks after chemoembolization. Selection of the T8
intercostal artery. Note that a laterally projecting outpouching of
stagnant contrast was noted, consistent with pseudoaneurysm. The
opacifying portion of the pseudoaneurysm measured about 2-3 cm
in size with a 5mm neck.
is better tolerated when irinotecan is given transarterially
with drug-eluting beads than when administered systemi-
cally. A study of chemoembolization with irinotecan-eluting
beads in treatment of metastatic CRC demonstrated a 50–
90% reduction of tumor marker carcinoembryonic anti-
gen (CEA), significant reduction of contrast enhancement
on postprocedure CT imaging, and downstaging of CRC
metastases [6]. However, the long-term effects of irinotecan
chemoembolization on these patients are not yet known.
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Figure 5: Aortogram, after coil embolization of the T8 intercostal
artery. Note that the postcoil embolization aortoagram demon-
strates no contrast opacification of the pseudoaneurysm lumen,
a coil mass measuring approximately 1.5 × 3.5 cm, and a gentle
regional concave deformity of the aorta, implying that the true
lumen of the pseudoaneurysm was larger than what opacified origi-
nally.
Several papers have demonstrated the palliative effects
of chemoembolization in the treatment of spinal metastases
from various primary cancers for patients who failed sys-
temic chemotherapy, are not amenable to surgical resection
or radiofrequency ablation of their spinal tumors, and have
a dominant soft tissue component that precludes treatment
with acrylic cement [8, 9]. The most recent study by Chiras
et al. demonstrated an 83% success rate in pain relief after
selective intra-arterial chemotherapy with carboplatin and
chemoembolization with pirabucin for metastatic kidney,
breast, lung, and gastrointestinal cancers and sarcomas to the
spine [8]. No major side effects were reported.
The use of irinotecan in combination with 5-FU/folinic
acid as a first- and second-line systemic treatment of
advanced colorectal cancer is on the rise [6, 7, 10].
Although systemic dosing is limited by intolerable toxicities,
mainly of the gastrointestinal and hematologic systems,
chemoembolization directs systemic doses on the targeted
site. Therefore, delivering chemotherapeutic drugs using
chemoembolization provides the benefit of concentrating
therapeutic doses directly on the lesions while avoiding
intolerable systemic side effects.
As mentioned previously, the long-term outcome of
irinotecan chemoembolization with drug-eluting beads is
still pending. The preliminary trial of chemoembolization
with irinotecan-eluting beads on colorectal cancermetastases
to the liver by Aliberti et al. demonstrated a 50–90% decrease
in CEA levels and a decrease in lesional contrast enhance-
ment [6]. Five months after irinotecan chemoembolization,
our patient’s CEA level decreased by 50%, and a decrease
in the size of the spinal metastasis was seen. The reported
side effects of the procedure from the Aliberti et al. data
Figure 6: CT T-spine without contrast five months after irinotecan
TACE and after pseudoaneurysm coil embolization. Note the
metastatic lesion in the left paravertebral/chest wall area which has
decreased in size, now measuring 5.5 cm× 5.2 cm.
when treating liver metastases, including abdominal pain,
shoulder pain, vomiting, mild asthenia, and alopecia, were
not experienced by our patient undergoing spinal metastasis
therapy at three months after procedure [6].
However, our patient experienced a side effect of a
pseudoaneurysm formation after chemoembolization with
irinotecan. This is a rare and interesting report of a
pseudoaneurysm after chemoembolization with irinotecan.
Our patient received approximately 20mg of irinotecan-
loaded beads in each of the three chemoembolized intercostal
arteries (T7–T9). Two weeks after the procedure, a pseudoa-
neurysm was discovered in the proximal segment of the T8
intercostal artery.
The overall incidence of intercostal artery pseudoa-
neurysms is rare, and only seven cases have been reported
in the literature [11–17]. Five of these cases were post-
surgical and two were traumatic. Although uncommon, the
occurrence of a pseudoaneurysm after chemoembolization
represents a risk that can threaten the patient’s outcome,
especially if the pseudoaneurysm ruptures.
Laboratory evidence of vascular damage from chemo-
therapeutic drugs for metastatic CRC has been reported only
for doxorubicin. At high doses, doxorubicin compromises
the vascular wall by causing excoriation and apoptosis
of endothelial and smooth muscle cells [18]. Although
irinotecan acts differently from doxorubicin, by inhibiting
topoisomerase I, there may be similarities in its ability
to damage arteries. Gene chip analyses from cancer cells
exposed to irinotecan have demonstrated upregulation of
proapoptotic genes and downregulation of antiapoptotic
genes [19]. This may suggest the possibility that like doxoru-
bicin, irinotecan may compromise the vascular endothelium.
In a study of irinotecan-eluting stents in rabbit aortas, high-
dose irinotecan also resulted in decreased vessel wall thick-
ness, increased necrosis, and inflammation [20]. Possibly,
through amechanism of proapoptotic gene activation and/or
necrosis, irinotecan weakens the vascular wall, thereby
increasing the risk of developing an aneurysm. Further
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studies to investigate irinotecan effect on the vascular wall
would therefore be helpful.
The standard treatment for patients with spinal metas-
tases from colorectal cancer is surgical resection and/or RFA.
In this case, the tumor had invaded the epidural space, lim-
iting these options. The standard traditional option would
have been radiation therapy with bland embolization. The
addition of effective chemotherapeutic drugs with embolic
material has gained favor for tumors not amenable to surgery
or RFA. To date, there is only one study [9] in its preliminary
stage demonstrating the long-term effects of chemoem-
bolization with irinotecan-eluting beads and no clinical
report of vascular consequences of irinotecan chemoem-
bolizations. The development of a pseudoaneurysm in the T8
intercostal artery secondary to traumatic vessel injury occur-
ring during catheterization cannot be completely excluded.
The cannulation, however, appeared atraumatic and was
completed by the attending interventional radiologist.
In summary, this case demonstrates the formation of a
pseudoaneurysm after transarterial chemoembolization with
irinotecan-eluting beads. Further studies are warranted to
evaluate the effects of irinotecan on the vascular wall and
the possibility that this could affect the long-term clinical
outcomes of irinotecan chemoembolization.
Consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images.
Conflict of Interests
The authors declare that they have no conflict of interests.
References
[1] L. C. Cummings, J. D. Payes, and G. S. Cooper, “Survival after
hepatic resection inmetastatic colorectal cancer: a population-
based study,” Cancer, vol. 109, no. 4, pp. 718–726, 2007.
[2] R. Adam, V. Delvart, G. Pascal et al., “Rescue surgery for unre-
sectable colorectal liver metastases downstaged by chemo-
therapy: a model to predict long-term survival,” Annals of
Surgery, vol. 240, no. 4, pp. 644–658, 2004.
[3] C. Fuchs, E. P. Mitchell, and P. M. Hoff, “Irinotecan in the
treatment of colorectal cancer,” Cancer Treatment Reviews, vol.
32, no. 7, pp. 491–503, 2006.
[4] A. Berenstein, P. Lasjaunias, and K. ter Brugge, Surgical
Neuroangiography, Springer, 2nd edition, 2004.
[5] J. Y. Douillard, D. Cunningham, A. D. Roth et al., “Irinotecan
combined with fluorouracil compared with fluorouracil alone.
as first-line treatment for metastatic colorectal cancer: a
multicentre randomised trial,” Lancet, vol. 355, no. 9209, pp.
1041–1047, 2000.
[6] C. Aliberti, M. Tilli, G. Benea, and G. Fiorentini, “Trans-
arterial chemoembolization (TACE) of liver metastases from
colorectal cancer using irinotecan-eluting beads: preliminary
results,” Anticancer Research, vol. 26, no. 5, pp. 3793–3795,
2006.
[7] G. Fiorentini, S. Rossi, P. Dentico et al., “Irinotecan hepatic
arterial infusion chemotherapy for hepatic metastases from
colorectal cancer: a phase II clinical study,” Tumori, vol. 89,
no. 4, pp. 382–384, 2003.
[8] J. Chiras, C. Adem, J. N. Valle´e, L. Spelle, E. Cormier, and
M. Rose, “Selective intra-arterial chemoembolization of pelvic
and spine bone metastases,” European Radiology, vol. 14, no.
10, pp. 1774–1780, 2004.
[9] T. Kato, R. Nemoto, and H. Mori, “Arterial chemoemboliza-
tion with mitomycin C microcapsules in the treatment of
primary or secondary carcinoma of the kidney, liver, bone and
intrapelvic organs,” Cancer, vol. 48, no. 3, pp. 674–680, 1981.
[10] H. C. Pitot, D. B. Wender, M. J. O’Connell et al., “Phase
II trial of irinotecan in patients with metastatic colorectal
carcinoma,” Journal of Clinical Oncology, vol. 15, no. 8, pp.
2910–2919, 1997.
[11] T. Aoki, A. Okada, M. Tsuchida, and J. Hayashi, “Rup-
tured intercostal artery pseudoaneurysm after blunt thoracic
trauma,” Thoracic and Cardiovascular Surgeon, vol. 51, no. 6,
pp. 346–347, 2003.
[12] W. G. Atherton and W. E. Morgan, “False aneurysm of an
intercostal artery after thoracoscopic sympathectomy,” Annals
of the Royal College of Surgeons of England, vol. 79, no. 3, pp.
229–230, 1997.
[13] R. Bluebond-Langner, P. A. Pinto, F. J. Kim, T. Hsu, and
T. W. Jarrett, “Recurrent bleeding from intercostal arterial
pseudoaneurysm after retroperitoneal laparoscopic radical
nephrectomy,” Urology, vol. 60, no. 6, article 1111, 2002.
[14] M. P. Callaway, P. Wilde, and G. Angelini, “Treatment of
a false aneurysm of an intercostal artery using a covered
intracoronary stent-graft and a radial artery puncture,” British
Journal of Radiology, vol. 73, no. 876, pp. 1317–1319, 2000.
[15] J. D. Casas, J. Perendreu, A. Gallart, and J. Muchart, “Inter-
costal artery pseudoaneurysm after a percutaneous biliary
procedure: diagnosis with CT and treatment with transarterial
embolization,” Journal of Computer Assisted Tomography, vol.
21, no. 5, pp. 729–730, 1997.
[16] S. Sekino, H. Takagi, H. Kubota, T. Kato, Y. Matsuno, and
T. Umemoto, “Intercostal artery pseudoaneurysm due to stab
wound,” Journal of Vascular Surgery, vol. 42, no. 2, pp. 352–
356, 2005.
[17] K. Yamakado, A. Nakatsuka, N. Tanaka, K. Takano, K.
Matsumura, and K. Takeda, “Transcatheter arterial emboliza-
tion of ruptured pseudoaneurysms with coils and n-butyl
cyanoacrylate,” Journal of Vascular and Interventional Radiol-
ogy, vol. 11, no. 1, pp. 66–72, 2000.
[18] T. Murata, H. Yamawaki, R. Yoshimoto et al., “Chronic effect
of doxorubicin on vascular endothelium assessed by organ
culture study,” Life Sciences, vol. 69, no. 22, pp. 2685–2695,
2001.
[19] H. Minderman, J. M. Conroy, K. L. O’Loughlin et al., “In vitro
and in vivo irinotecan-induced changes in expression profiles
of cell cycle and apoptosis-associated genes in acute myeloid
leukemia cells,” Molecular Cancer Therapeutics, vol. 4, no. 6,
pp. 885–900, 2005.
[20] D. H. Berrocal, G. E. Gonzalez, C. Morales, R. J. Gelpi, and
L. R. Grinfeid, “Irinotecan-eluting stents inhibited neointimal
proliferation in hypercholesterolemic rabbit aortas,” Catheter-
ization and Cardiovascular Interventions, vol. 68, no. 1, pp. 89–
96, 2006.
